Real-World Evidence Under Consideration For Use In Interchangeable Biosimilars Applications

 
• By Derrick Gingery
  
Questions to be answered
Labeling, promotional and other draft interchangeability guidances are required to be issued during BsUFA III. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics